Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India

Tyrosine kinase inhibitors such as sunitinib and pazopanib are the mainstay of treatment of metastatic renal cell carcinoma (mRCC) in India. However, pembrolizumab and nivolumab have shown significant improvement in the median progression-free survival and overall survival among patients with mRCC....

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Dharna, Singh, Ashish, Gupta, Nidhi, Mehra, Nikita, Bahuguna, Pankaj, Aggarwal, Vipul, Krishnamurthy, Manjunath Nookala, Roy, Partha Sarathi, Malhotra, Pankaj, Gupta, Sudeep, Kumar, Lalit, Kataki, Amal, Prinja, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166401/
https://www.ncbi.nlm.nih.gov/pubmed/36795991
http://dx.doi.org/10.1200/GO.22.00246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166401/
https://www.ncbi.nlm.nih.gov/pubmed/36795991
http://dx.doi.org/10.1200/GO.22.00246

Ejemplares similares